NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free MNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.1350-Day Range$0.14▼$0.7552-Week Range$0.75▼$6.42Volume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial Media Get Mallinckrodt alerts: Email Address Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Mallinckrodt Stock (NYSE:MNK)Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. MNK Stock News HeadlinesMarch 4, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 4, 2024 | finance.yahoo.comMallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 1, 2024 | markets.businessinsider.comMallinckrodt Says FDA Grants SNDA For Acthar Gel Single-Dose Pre-Filled SelfJect InjectorFebruary 24, 2024 | benzinga.comMallinckrodt Stock (OTC:MCKPF) Dividends: History, Yield and DatesFebruary 21, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS CELLEX Photopheresis System Treatment at the 2024 Tandem MeetingsFebruary 3, 2024 | msn.comMallinckrodt Announces Executive Appointments and Incentive PlansJanuary 31, 2024 | morningstar.comMallinckrodt PLC Ordinary Shares - NewMarch 19, 2024 | Paradigm Press (Ad)Biden out June 13?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.January 9, 2024 | msn.comMallinckrodt to discontinue StrataGraft due to slow uptakeDecember 27, 2023 | finance.yahoo.comMallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality IndexDecember 7, 2023 | sg.finance.yahoo.comMallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-CylinderDecember 1, 2023 | msn.comMallinckrodt Avoids $40 Million SEC Fine in Medicaid Overcharge CaseNovember 16, 2023 | finance.yahoo.comMallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comMallinckrodt emerges from bankruptcyNovember 14, 2023 | finance.yahoo.comMallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11October 11, 2023 | msn.comMallinckrodt sees emerging from Chapter 11 by end of yearOctober 11, 2023 | msn.comMallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1 Billion in Opioid PaymentsOctober 11, 2023 | finance.yahoo.comMallinckrodt Approved to End Bankruptcy, Reduce Opioid PaymentsOctober 10, 2023 | reuters.comMallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlementOctober 10, 2023 | finance.yahoo.comMallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring PlanSeptember 20, 2023 | msn.comFirm Retention Summary: MallinckrodtSeptember 20, 2023 | msn.comDrug giant Mallinckrodt enters second Irish ExaminershipSeptember 19, 2023 | msn.comBankrupt Drugmaker Mallinckrodt Considers Sale of Opioid BusinessSeptember 1, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)August 31, 2023 | finance.yahoo.comMallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)August 30, 2023 | finance.yahoo.comMallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing OperationsSee More Headlines Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2020Today3/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / Book0.00Miscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMark C. TrudeauPresident, Chief Executive Officer & DirectorBryan M. ReasonsChief Financial Officer & Executive Vice PresidentSteven Joseph RomanoChief Scientific Officer & Executive VPBabatunde Adekunle OtulanaChief Medical Officer & Senior Vice PresidentMichele RobertsonChief Compliance Officer & Senior Vice PresidentKey CompetitorsPaxMedicaNASDAQ:PXMD180 Life SciencesNASDAQ:ATNFDermata TherapeuticsNASDAQ:DRMABiodexa PharmaceuticalsNASDAQ:BDRXSciSparcNASDAQ:SPRCView All Competitors MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) posted its earnings results on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The firm earned $700.90 million during the quarter, compared to analysts' expectations of $630.19 million. Mallinckrodt had a negative net margin of 82.59% and a positive trailing twelve-month return on equity of 20.32%. The business's revenue for the quarter was down 14.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.53 earnings per share. Read the conference call transcript. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD). This page (NYSE:MNK) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.